Mutamba et al., 2011 - Google Patents
XRCC1 and base excision repair balance in response to nitric oxideMutamba et al., 2011
View PDF- Document ID
- 8366230428618117304
- Author
- Mutamba J
- Svilar D
- Prasongtanakij S
- Wang X
- Lin Y
- Dedon P
- Sobol R
- Engelward B
- Publication year
- Publication venue
- DNA repair
External Links
Snippet
Inflammation associated reactive oxygen and nitrogen species (RONs), including peroxynitrite (ONOO−) and nitric oxide (NO), create base lesions that potentially play a role in the toxicity and large genomic rearrangements associated with many malignancies. Little …
- 108009000276 Base Excision Repair 0 title abstract description 84
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mutamba et al. | XRCC1 and base excision repair balance in response to nitric oxide | |
| Katyal et al. | TDP1 facilitates chromosomal single‐strand break repair in neurons and is neuroprotective in vivo | |
| Donley et al. | Small molecule inhibitors of 8-oxoguanine DNA glycosylase-1 (OGG1) | |
| Wagenaar et al. | Resistance to vemurafenib resulting from a novel mutation in the BRAFV 600 E kinase domain | |
| US6376508B1 (en) | Treatments for spinal muscular atrophy | |
| Cousineau et al. | EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: implications for chromosomal instability/recombination syndromes as checkpoint diseases | |
| AU2014348291A9 (en) | Compositions and methods of using transposons | |
| US8809296B2 (en) | Apoptosis inducer for cancer cell | |
| JP2022512773A (en) | Prevention of age-related cloned hematopoies and related diseases | |
| Fan et al. | XRCC1 down‐regulation in human cells leads to DNA‐damaging agent hypersensitivity, elevated sister chromatid exchange, and reduced survival of BRCA2 mutant cells | |
| Stachelek et al. | Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation | |
| CA3218849A1 (en) | Variants of sirt6 for use in preventing and/or treating age-related diseases | |
| US20110212101A1 (en) | Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancers | |
| Lee et al. | RAS induced senescence of skin keratinocytes is mediated through rho‐associated protein kinase (ROCK) | |
| Bertolin et al. | The mechanism of checkpoint-dependent DNA replication fork stabilization in human cells | |
| WO2020061391A1 (en) | Methods for inhibiting tumor cells using inhibitors of foxo3a antagonists | |
| US6573300B2 (en) | Hydroxyurea treatment for spinal muscular atrophy | |
| Gullotta et al. | Targeting the DNA double strand breaks repair for cancer therapy | |
| Ferreira et al. | The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high MYC malignancies | |
| JP7062292B2 (en) | Phospholipid hydroperoxide-dependent cell death inhibitor and phospholipid hydroperoxide-dependent cell death-related disease prophylaxis or therapeutic agent | |
| Wojnicki | The role of BLM and RecQL4 helicases in defining the response of glioma cells to chemotherapeutics: PhD thesis | |
| US20250257357A1 (en) | Treatment of h3.3-mutant brain cancer with pnkp inhibitors | |
| JP6573408B2 (en) | Method and kit for detecting phospholipid hydroperoxide-dependent cell death | |
| Zhao | APE2 Is a General Regulator of the ATR-Chk1 DNA Damage Response | |
| JAQUET | " Identification of pharmacological inhibitors of NADPH oxidases for the treatment of oxidative stress-derived pathologies |